Short Interest in Septerna, Inc. (NASDAQ:SEPN) Increases By 36.0%
by Scott Moore · The Cerbat GemSepterna, Inc. (NASDAQ:SEPN – Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,941,013 shares, an increase of 36.0% from the December 31st total of 1,427,098 shares. Currently, 4.5% of the company’s shares are sold short. Based on an average daily volume of 319,319 shares, the days-to-cover ratio is presently 6.1 days. Based on an average daily volume of 319,319 shares, the days-to-cover ratio is presently 6.1 days. Currently, 4.5% of the company’s shares are sold short.
Insider Activity at Septerna
In related news, SVP Daniel D. Long sold 3,501 shares of Septerna stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the transaction, the senior vice president directly owned 92,911 shares of the company’s stock, valued at $1,677,972.66. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.30% of the company’s stock.
Institutional Trading of Septerna
A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. Russell Investments Group Ltd. acquired a new stake in shares of Septerna during the third quarter valued at approximately $36,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Septerna in the 4th quarter worth approximately $61,000. Covestor Ltd boosted its position in shares of Septerna by 55.8% during the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after acquiring an additional 1,296 shares in the last quarter. BNP Paribas Financial Markets grew its position in Septerna by 88.0% in the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after acquiring an additional 1,945 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares during the last quarter.
Septerna Stock Up 7.3%
Shares of NASDAQ:SEPN opened at $25.04 on Tuesday. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -16.58 and a beta of 3.85. The business has a 50-day moving average price of $26.82 and a 200-day moving average price of $20.40. Septerna has a 52-week low of $4.17 and a 52-week high of $30.50.
Septerna (NASDAQ:SEPN – Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The company had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. As a group, equities analysts anticipate that Septerna will post -7.11 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Truist Financial initiated coverage on Septerna in a report on Monday, December 15th. They issued a “buy” rating and a $34.00 target price for the company. Zacks Research downgraded shares of Septerna from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Jones Trading started coverage on Septerna in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price target for the company. Finally, HC Wainwright boosted their target price on shares of Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.
Get Our Latest Stock Report on SEPN
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.